English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT04016805 /

UTX-TGR-208

A Phase 2 Study To Assess The Efficacy And Safety Of Ublituximab And Umbralisib In Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib Or Venetoclax

DISEASE GROUP:
Lymphoma
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: